Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials
[en] In childhood B-cell precursor acute lymphoblastic leukaemias (BCP-ALL), the presence of an ETV6-RUNX1 fusion transcript defines one of the most prevalent genetic subgroups, together with the high hyperdiploidy (HeH) ALL. Although ETV6-RUNX1pos ALLs are associated with favourable outcome, their proper treatment strategies remain debatable, some groups suggesting crucial impact of upfront intensive treatment while others favour low-intensity antimetabolite-based therapy.
Disciplines :
Pediatrics Hematology
Author, co-author :
Piette, Caroline ; Centre Hospitalier Régionale de la Citadelle (Liège) - CHR CITADELLE > Service Universitaire de Pédiatrie ULiège > Hémato-Oncologie Pédiatrique
Suciu, S
Clappier, E
Bertrand, Y
Drunat, S
Girard, S
Yacouben, K
Plat, G
Dastugue, N
Mazingue, F
Grardel, N
Van Roy, N
Uyttebroeck, A
Costa, V
Minckes, O
Sirvent, N
Simon, P
Lutz, P
Ferster, A
Pluchart, C
Poirée, M
Freycon, C
Dresse, Marie-Françoise ; Centre Hospitalier Universitaire de Liège - CHU > Hémato-Oncologie Pédiatrique > Service de pédiatrie (CHR)
Differential impact of drugs on the outcome of ETV6-RUNX1 positive childhood B-cell precursor acute lymphoblastic leukaemia: results of the EORTC CLG 58881 and 58951 trials
Avigad S, Kuperstein G, Zilberstein J, Liberzon E, Stark B, Gelernter I et al. TELAML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia. Leukemia 1999; 13: 481-483.
Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM et al. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood 1997; 89: 1143-1146.
Vilmer E, Suciu S, Ferster A, Bertrand Y, Cave H, Thyss A et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Leukemia 2000; 14: 2257-2266.
De Moerloose B, Suciu S, Bertrand Y, Mazingue F, Robert A, Uyttebroeck A et al. Improved outcome with pulses of vincristine and corticosteroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and lymphoblastic non-Hodgkin lymphoma (NHL): Report of the EORTC randomized phase 3 trial 58951. Blood 2010; 116: 36-44.
Domenech C, Suciu S, De Moerloose B, Mazingue F, Plat G, Ferster A et al. Dexamethasone (6 mg/m2/day) and prednisolone (60 mg/m2/day) were equally effective as induction therapy for childhood acute lymphoblastic leukemia in the EORTC CLG 58951 randomized trial. Haematologica 2014; 99: 1220-1227.
Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized EuropeanOrganisation for Research and Treatment of Cancer,Children's Leukemia Group phase 3 trial. Blood 2002; 99: 2734-2739.
Mondelaers V, Suciu S, De Moerloose B, Ferster A, Mazingue F, Plat G et al. Prolonged E. Coli asparaginase therapy does not improve significantly the outcome for children with low and average risk acute lymphoblastic leukemia (ALL) and non Hodgkin lymphoma (NHL): Final Report of the EORTC-CLG Randomized Phase III Trial 58951. Blood 2012; 120: abstract 134.
Loh ML, Goldwasser MA, Silverman LB, Poon WM, Vattikuti S, Cardoso A et al. Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. Blood 2006; 107: 4508-4513.
Rubnitz JE, Wichlan D, Devidas M, Shuster J, Linda SB, Kurtzberg J et al. Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: A children's oncology group study. J Clin Oncol 2008; 26: 2186-2191.
Bhojwani D, Pei D, Sandlund JT, Jeha S, Ribeiro RC, Rubnitz JE et al. ETV6-RUNX1- positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy. Leukemia 2012; 26: 265-70.
Möricke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G et al. Dexamethasone vs prednisone in induction treatment of pediatric ALL : results of the randomized trial AIEOP-BFM ALL 2000. Blood 2016; 127: 2101-2113.
van der Werff Ten Bosch J, Suciu S, Thyss A, Bertrand Y, Norton L, Mazingue F et al. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG. Leukemia 2005; 19: 721-726.
Schmiegelow K, Al-modhwahi I, Andersen MK, Behrendtz M, Hasle H, Heyman M et al. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHOALL-92 study. Blood 2012; 113: 6077-6084.
Zaza G, Yang W, Kager L, Cheok M, Downing J, Pui CH et al. Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis. Blood 2004; 104: 1435-1441.
Masson E, Synold TW, Relling MV, Schuetz JD, Sandlund JT, Pui C-H et al. Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. Leukemia 1996; 10: 56-60.
